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Abstract: Research has investigated 25-hydroxyvitamin D (25(OH)D) levels in the Atopic Dermatitis 
(AD) population, as well as changes in AD severity after vitamin D (VitD) supplementation. We 
performed an up-to-date systematic review and meta-analysis of these findings. Electronic searches 
of MEDLINE, EMBASE and COCHRANE up to February 2018 were performed. Observational studies 
comparing 25(OH)D between AD patients and controls, as well as trials documenting baseline serum 
25(OH)D levels and clinical severity by either SCORAD/EASI scores, were included. Of the 1085 
articles retrieved, sixteen were included. A meta-analysis of eleven studies of AD patients vs. healthy 
controls (HC) found a mean difference of −14 nmol/L (95% CI −25 to −2) for all studies and −16 nmol/L 
(95% CI −31 to −1) for the paediatric studies alone. A meta-analysis of three VitD supplementation 
trials found lower SCORAD by −11 points (95% CI −13 to −9, p < 0.00001). This surpasses the Minimal 
Clinical Important Difference for AD of 9.0 points (by 22%). There were greater improvements in trials 
lasting three months and the mean weighted dose of all trials was 1500–1600 IU/daily. Overall, the AD 
population, especially the paediatric subset, may be at high-risk for lower serum 25(OH)D. 
Supplementation with around 1600 IU/daily results in a clinically meaningful AD severity reduction. 
Keywords: 25-hydroxyvitamin D; 25(OH)D; systematic review; case-control; supplementation; meta-
analysis; atopic dermatitis; paediatric; randomised control trial; SCORAD 
 
1. Introduction 
Atopic Dermatitis (AD) is a chronic recurrent inflammatory disease of the skin characterised by 
pruritus and inflamed lesions, involving specific areas of the body and causing generalised xerotic skin. 
As the disease progresses from acute to subacute, to chronic stages, excoriation from scratching and a 
propensity to secondary infections leads to oozing lesions and further pruritus. Severity of pruritis is 
associated with quality of life. Scores on the PO-SCORAD (patient oriented SCORAD) questionnaire, 
which includes a visual analogue scale for pruritis severity, are associated with measures of quality of 
life [1,2]. 
Eighty-five percent of AD is seen in children, of which 30% continue to suffer in their adult years 
[3]. There are an estimated 15 million suffers in the United Kingdom (UK) [4] and in the United States 
(US); 25% of children and 7% of adults have AD [3]. The incidence of AD is growing world-wide, 
especially in urbanised countries, with a higher rate in northern latitudes during the winter months [5]. 
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The financial strain of AD at the level of individual, family and the public healthcare system cannot be 
underestimated. A 4.2 billion USD per year cost was estimated for the US alone with individual 
healthcare costs for AD patients higher by between 28.3% and 67.9% compared to non-AD patients 
[6,7]. 
AD pathology involves a complex interplay of barrier issues of skin and various dysfunctions in 
host innate and adaptive immune systems. These include high IgE, eosinophil and distinct T-helper cell 
populations as well as cytokine dysmodulation [8–10]. Bacterial and viral infestation from 
Staphylococcus Aureus and Herpes Simplex infections exacerbate pre-existing AD. However, factors 
contributing to long-term remission of AD are currently unknown [11,12]. Presently, due to no 
identified clinical biomarkers, quantitative and qualitative clinical tools are used to gauge severity of 
clinical presentation, with the Scoring Atopic Dermatitis index (SCORAD) being the most validated 
and commonly used in clinical research. The severity scale for SCORAD is pegged at Mild AD <25 
points, Moderate AD >25 points and Severe AD >50 points [13,14]. 
There is much interest in the potential role of vitamin D deficiency in the development of AD, from 
multiple lines of research evidence. First, research has documented the aggravation of AD in winter, 
especially in higher latitude countries where serum 25(OH)D tends to be particularly low in this season 
[5]. Second, improvement in AD symptoms in patients has been observed in research studies on VitD 
supplementation [15,16]. Third, genetic polymorphisms including those of the Vitamin D Receptor 
(VDR) and a filaggrin gene mutation (up to 50% of the AD population, depending on specific mutation) 
have been identified as contributors to the development of AD [17,18]. 
Of note, Vitamin D3 (VitD3) is known to play a role in the skin barrier function, as it modulates 
structural proteins of the cornified dermis layer, regulating the glycoseramides essential for the 
hydrating protective lipid barrier which keeps the skin moisturized [19]. It modulates innate immunity 
via the production of the anti-microbial peptides (AMPs) cathelicidin and defensin which can help 
reduce skin infection risk [20]. In addition, Amon et al. (2018) discussed how vitamin D has inhibitory 
effects on monocyte production (via Toll-like receptors) and well as inhibiting dendritic cell activity 
and increasing mast cell release of IL10 [21]. They also discussed how vitamin D reduces the release of 
proinflammatory cytokines from Th1 cells and inhibits the release of IgE by reducing B cell function 
[21]. These mechanisms would theoretically aid the reduction of chronic inflammation in the skin. 
The optimum 25(OH)D level for the prevention of, or rehabilitation of, inflammatory skin diseases 
is yet unknown. At present, for bone health, the US Endocrine Society recommends that serum 
25(OH)D levels <50 nmol/L (20 ng/mL) are classified as deficient and 53–73 nmol/L (21–29 ng/mL) as 
insufficient. The UK Scientific Advisory Committee on Nutrition recommendations are more 
conservative, suggesting 25 nmol/L or higher as a population protective level for bone health [22]. These 
are population estimates and the physiological need for vitamin D may be higher in some clinical 
conditions. More research is now required to assess the optimum serum 25(OH)D concentration 
specifically required for those with AD, as well as assessing the current 25(OH)D status in AD patients. 
Two previous systematic reviews and meta-analysis in 2016 on vitamin D and AD [12,23] have 
found a lower serum 25(OH)D in AD patients compared with non-AD patients [12] as well as a reduced 
severity of disease in AD patients after vitamin D supplementation [12,23]. However, new research has 
been conducted since the publication of these reviews and so there is a clear need for this systematic 
review and meta-analysis to be updated. A recent systematic review reviewed the area [24] but did not 
include a meta-analysis so there was no updated effect size using data from recent trials. The aim of 
this work therefore was to provide an updated review of observational and intervention trial data on 
the role of VitD in AD, including all published studies up to February 2018. First, we assessed the mean 
difference, in observational studies, between 25(OH)D concentration in AD patients and HC, with a 
sub-analysis of adult and paediatric populations separately. This was to gauge differences in 25(OH)D 
from normal which may be of clinical importance. Second, we assessed the impact of VitD 
supplementation on AD severity (change in SCORAD index), quantifying the role of VitD dosage and 
trial duration, to both support further research and advise clinical guidelines. 
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2. Methods 
2.1. Search Procedures 
A systematic search was conducted on the MEDLINE database via Pubmed 
(https://www.ncbi.nlm.nih.gov/pubmed/). The EMBASE database (https://www.embase.com/login) 
and the COCHRANE DATABASE for registered trials (http://cochranelibrary-
wiley.com/cochranelibrary/search?searchRow.searchOptions.searchProducts=clinicalTrialsDoi) were 
also searched. For search terms, MESH i.e., Medical Subject Headings (MESH) were used along with 
pre-text terms. Search terms used for all three databases included: “Vitamin D AND Atopic 
Dermatitis”; “Vitamin D AND Eczema”; “25 Hydroxy Vit D AND Atopic Dermatitis”; “Vitamin D 
AND Atopic Dermatitis AND children”. 
Following the recommendations by the Cochrane Database of Systematic Reviews 
(http://www.cochranelibrary.com/), reference lists searches were made to double-check for appropriate 
papers not previously located in the electronic searches. We also searched for grey literature such as 
abstracts from conference presentations. Researchers with abstract publications in the field were 
contacted via email and phone calls to request complete study results and data sets. Researchers of fully 
published papers were also contacted for any missing data. The searches covered papers from January 
1963 to February 2018. In studies which included both adult and child participants, published data and 
raw unpublished data of both adult and child participants were obtained to enable sub-analysis for the 
adult and child populations. This review did not require ethical approval as it only involved analysis 
of already collected data. 
2.2. Eligibility Criteria for Inclusion and Data Extraction 
Observational studies (case-control design) as well as interventional studies, including 
randomized double-blind placebo control trials, non-randomized placebo control trials, clinical 
intervention and audit trials were assessed. We included all human studies published in the English 
language. Inclusion criteria were as follows: Age group >1 year, including both males and females. 
Exclusion criteria were as follows: Pregnant women, infants <1 year. Intervention studies were only 
included if they had an assessment of serum 25(OH)D levels at baseline. For both observational and 
intervention studies, the SCORAD and/or the EASI score needed to be included in the study for 
inclusion in the systematic review. This helped support clear mathematically calculable data in terms 
of proof of AD and severity of presence of AD in observational studies and improvement or 
exacerbation of AD during the interventional trials. For interventional studies, this enabled calculation 
of an effect size for the effect of VitD supplementation on AD severity, giving a quantifiable estimate 
to assess the clinical relevance of the results. Search procedures were documented using the PRISMA 
protocol. 
2.3. Primary Outcomes 
1. From observational studies, serum 25(OH)D levels in AD patients versus HC. 
2. From interventional trials, changes in SCORAD or EASI score in the VitD supplemented AD group 
compared to the placebo supplemented AD group. 
2.4. Secondary Outcomes 
1. The relationship between serum 25(OH)D levels in AD with SCORAD or EASI score. 
2. Effects of VitD supplementation on secondary infections of skin in AD. 
3. The relationship between serum 25(OH)D levels, serum IgE levels and total eosinophil count (TEC) 
in the AD population and HC, including changes in these post-supplementation. 
4. In interventional trials only: Effects of the co-usage of topical steroids. 
5. The relationship, in AD patients, between serum 25(OH)D levels and cathelicidin LL-37 or 
Cathelicidin Antimicrobial Peptide (CAMP) and changes post-supplementation. 
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6. The relationship, in AD patients, between serum 25(OH)D levels and serum cytokines, with 
changes post-supplementation. 
7. The relationship between serum 25(OH)D levels and atopic sensitisation. 
2.5. Statistical Analysis 
The p-value, confidence interval, and effect estimate of all primary outcomes were extracted. For 
observational studies, included in the meta-analysis of comparison of 25(OH)D levels in AD and HC, 
the mean ± standard deviation (SD) of 25(OH)D levels of both groups were extracted, as well as n 
(number of participants) in each group. Serum 25(OH)D concentrations were inputted into the meta-
analyses in nmol/L. The serum 25(OH)D concentrations in two studies were presented in nmol/L 
[25,26]. The other nine studies [27–35] presented 25(OH)D concentrations in ng/mL but were converted 
to nmol/L using the standard formula: nmol/L = 2.5*ng/mL. 
For interventional studies, as well as the number of participants (n) in the intervention group and 
the control group, the SCORAD score was extracted at baseline and after intervention (mean ± SD). In 
one study [36], the post intervention score was represented as a percentage of improvement so the mean 
± SD were calculated accordingly for this study. For supplementation trials, VitD dose and trial 
duration were also extracted. 
Review Manager (Rev Man 5·3; Cochrane Collaboration, London, UK) was used to perform the 
meta-analyses. The Newcastle–Ottawa Scale and the Cochrane Risk of Bias Scale were used to assess 
the quality of observational studies and interventional studies, respectively. The I2 statistic was used to 
assess heterogeneity between study outcomes and, due to significant between-study heterogeneity, the 
meta-analyses were conducted using the random effects model. 
A planned a priori sub-analysis, for adult and paediatric specific data, was undertaken for the 
meta-analysis of serum 25(OH)D levels in AD and HC. Data from the two studies with data for separate 
age groups [31,32] were extracted from their published papers and additional raw data were also 
supplied by their research teams. The meta-analysis of interventional studies was undertaken using 
changes in SCORAD score between baseline and post-VitD supplementation, a weighted mean dose 
across this meta-analysis was calculated. This was calculated manually by multiplying each trial dose 
by the weighting given for that study in the meta-analysis and summing up the dosage to represent the 
100% weighted mean dose. A planned a priori sub-analysis of interventional trials was done to assess 
the difference in SCORAD score changes in relation to VitD dosage and time period of trials. Inspection 
of funnel plots were undertaken to assess potential publication bias (subject to restrictions incurred by 
the number of studies available for analysis). Sensitivity analyses were also conducted when the 
analysis contained more than two studies. 
3. Results 
3.1. Systematic Review 
Results of the systematic literature searches are shown in Figure 1. The textual Systematic Review 
assessing results for each outcome and its relation with 25(OH)D status can be viewed in the 
Supplemental File. Tables 1–4 illustrate the characteristics and outcomes of the included studies. 
Results of the Newcastle–Ottawa Scale and the Cochrane Risk of Bias Scale scoring can be seen in 
Supplementary Tables S1 and S2.
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Table 1. Observational case-control studies of serum 25(OH)D levels in atopic dermatitis individuals compared to healthy controls. 
Case 
Control 
Study 
Participants Population-Total N, ‘n-AD’, n-HC Primary Study Outcome 
Review 
Outcome Serum 
25(OH)D Levels 
Observed  
p 
Value Secondary Study Outcome 
Cheon 2015 
(South 
Korea) [27] 
Paediatric OPD, median age 6 
years 
N: 123, n-AD: 91, n-HC: 32 
Serum 25(OH)D levels significantly lower in AD 
compared to HC. Lower levels in Moderate and 
Severe AD compared to Mild AD. 
AD = 23 ± 2 
ng/mL HC= 36 ± 
3 ng/mL 
<0.05   
D’Auria 
2017 (Italy) 
[28] 
Paediatric OPD. Age 1–14 
years, 43% Caucasians, skin 
phototype II or III according 
to Fitzpatrick skin type 
N: 95, analysis- n-AD: 52, n-HC 43 
Serum 25(OH)D levels statistically significant higher 
in HC than AD even after adjustment for age, sex 
and season  
(p = 0.04) 
AD = 19 ng/mL, 
HC = 25 ng/mL 0.04 
No association was found between serum 25(OH)D levels and AD 
severity. 
El Taieb 2013 
(Egypt) [30] 
Patients from the OPD Clinic. 
Age 2–12 years N: 59, n-AD: 29, n-HC: 30 
Mean Value of Serum Vitamin D in AD is much 
lower than HC. 
AD = 5 ± 2 
ng/mL, HC = 29 
± 2 ng/mL  
<0.001 
Mean Serum 25(OH)D levels significantly higher in Mild AD (15 ± 4 
ng/mL) vs. Moderate AD (6 ± 3 ng/mL) or Severe AD (0.3 ± 0.1 ng/mL). 
Individual SCORAD values showed significant inverse correlation with 
serum 25(OH) D Levels, r = −0.88, p = 0.001 
Han 2015 
[31] 
Patients: adult >18 years, child 
<18. Age: Adults: 26.8 ± 8.25 
(18–51), Child 9.5 ± 4.27 (1–16) 
years 
N: 212, Adults n-AD: 39, n-HC: 70, 
Children n-AD: 33, n-HC: 70 
Serum 25(OH)D level significantly lower in AD 
children, not statistically different in AD adults.  
Overall not statistically different between 72 AD 
patients (12.43 ± 4.66 ng/mL) vs. 140 control (13.49 ± 
6.23 ng/mL) (p = 0.05)  
All adults + 76% children with AD showed deficient 
levels of Serum 25(OH)D levels. 
Child-AD = 15 ± 
5 ng/mL, 
Child-HC = 16 ± 
7 ng/mL. 
Adults-AD = 10 
± 4 ng/mL. 
Adult-HC = 11 ± 
4 ng/mL 
Child 
0.04 
Difference in serum 25(OH)D levels of different AD severity not 
statistically different (p > 0.05). Significant inverse correlation between 
BMI and VitD level in AD (r = −0.32, p = 0.007) and HC (r = −0.335, p = 
0.009). Significant inverse correlation between SCORAD and serum LL-
37(r = −0.3, p = 0.01) for total population and only significant in adults after 
subdividing (r = −0.36, p = 0.025) 
Noh 2014 
(South 
Korea) [32] 
Patients AD-82, Asthma-38 
HC-49 
N:169, n-AD: 82, n-HC: 49. Analysis 
done with n-AD: 61, n-HC: 34 
AD patients had significantly lower Vitamin D levels 
compared to Asthmatic pts and healthy Controls (p = 
0.01 and p < 0.001). Statistically significant negative 
correlation between Serum 25(OH)D levels and 
eczema involvement of the total area (r = −0.376, p = 
0.001)  
HC = 11 ± 1 
ng/mL AD = 10 
± 1 ng/mL 
0.001 
Significant inverse correlation was observed for serum 25(OH)D levels 
and total body affected by eczema (r = −0.38, p = 0.001) Correlation found 
between serum 25(OH)D levels and different dermal area manifestations, 
age, eosinophil count, serum Ig E levels. 
Sharma 2017 
(India) [25] 
Patients from Dermatological 
OPD, ages 2–18 years  N: 80, n-AD: 40, n-HC: 40 
Lower Serum 25(OH)D levels in AD was statistically 
highly significant compared to HC 
AD = 30 nmol/L, 
HC = 54 nmol/L <0.001 
Significantly inverse correlation between Serum25(OH)D levels and 
SCORAD index. Mean serum 25(OH)D levels were significantly lower in 
AD vs. HC with superficial bacterial, fungal, viral infection. Levels were 
deficient in patients with AD (<20 nmol/L) and insufficient in (20–29 
nmol/L) in HC with cutaneous infection. 
Su 2017 
(Turkey) [34] 
Dermatology OPD, 2–16 years 
(mean 8·37); N:97, n-AD:60, n-HC: 37 
No statistical significant difference in Mean Serum 
25(OH)D levels of AD and HC. 
AD = 16 ± 7 
ng/mL HC = 20 
± 10 ng/mL 
0.07 
Significant inverse relationship between SCORAD scores and Serum 
25(OH)D levels. Serum 25(OH)D levels statistically significantly lower in 
moderate and severe AD compared with mild AD (p = 0·001, p = 0·004) Vit 
D showed negative correlation with Serum IgE levels (p = 0·007) 
Wang 2014 
(Hong 
Kong)[26] 
Paediatric OPD (n = 405) 
Secondary school 
epidemiological study for 
obesity and diabetics (n = 95) 
N:826, n-AD: 498, n-HC:328 
serum 25(OH)D levels higher in HC than AD. 
Inverse association seen between Serum VitD levels 
and SCORAD, Ness Scores. 
AD=29 ± 15 
HC=34 ± 15 nM <0.001 
Higher percentage of AD had Serum 25(OH)D <25nM vs HC (47.8% vs. 
26.6%). Serum 25(OH)D levels showed inverse associations with short-
term, long-term AD severity, serum IgE and eosinophil levels. 
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Table 2. Showing data of serum 25(0H)D levels in the atopic dermatitis participants compared to healthy controls in included studies. 
Study Case Study Type 
n-
Cases 
n-
HC 
Age: Adult 
‘A’ Child 
‘C’ 
Serum 
25(OH)VitD 
Levels AD 
Baseline (ng/mL) 
Serum 
25(OH)VitD 
Levels AD 
Baseline 
(nmol/L) 
Serum 25(OH)VitD 
Levels Healthy 
Controls (ng/mL) 
Serum 25(OH)VitD 
Levels Healthy 
Controls 
(nmol/L) 
p Value  
Geographical 
Location  
by  
Latitude 
VitD 
Deficient (D) 
Sufficient(S) 
Insufficient(I) 
Cheon 2015 
[27] Case-Control 91 32 C 23 ± 2 58 ± 4 36 ± 3 90 ± 7 <0.05 
Korea 
37.7 
AD- I 
Controls- S 
D’Auria 2017 
[28] Case-Control 52 43 C 19 ± 7 48 ± 18 25 ± 13 62 ± 31 0.04 
Milan, Italy 
45.5 
AD- D 
Controls- I 
Di Filippo 
2015 [29] Interventional 39 20 C 23 ± 8 57 ± 20 20 ± 3 50 ± 8 Not Specified 
Cheiti, Italy 
42.4 
AD- I 
Controls- I 
El Taieb 2013 
[30] Case-Control 29 30 C 5 ± 2 14 ± 5 29 ± 2 72 ± 6 <0.001 
Egypt 
26.8 
AD- D 
Controls- I 
Han 2015 [31] Case-Control 72 140 A,C 12 ± 5 31 ± 12 14 ± 6 34 ± 16 p > 0.05 Korea 
37.7 
AD- D 
Controls -D 
Han 2015 
Adult [31] 
Case-Control 39 70 A 10 ± 3 26 ± 8 11 ± 4 27 ± 11 p > 0.05 
Korea 
37.7 
AD- D 
Controls- D 
Han 2015 
Child [31] Case-Control 33 70 C 15 ± 5 38 ± 11·58 16 ± 7 41 ± 17 0.04 
Korea 
37.7 
AD- D 
Controls- D 
Hata 2014 [35] Interventional 30 30 A,C 28 ± 11 71 ± 28 30 ± 12 75 ± 31 Not specified  Multicentric 
32.7–45.5 
AD- I 
Controls- S 
Noh 2014 [32] Case-Control 82 49 A,C 10 ± 0.6 24 ± 2 11 ± 1 28 ± 2 0.001 Korea 
37. 
AD- D 
Controls -D 
Noh 2014—
Child [32] Case-Control 27 12 C 11 ± 5 27 ± 12 13 ± 5 31 ± 14 
Retrieved from 
supplied data  
Korea 
37.7 
AD- D 
Controls- D 
Noh 2014 
Adult [32] Case-Control 34 23 A 9 ± 4 21 ± 11 10 ± 6 25 ± 15 
Retrieved from 
supplied data  
Korea 
37.7 
AD- D 
Controls- D 
Samochocki 
2013 [33] Interventional 95 58 A 23 ± 13 58 ± 33 24 ± 13 59 ± 32 >0.05 
Poland 
51.9 
AD- D 
Controls- D 
Sharma 2017 
[25] Case-Control 40 40 C 12 ± 3 30 ± 7 21 ± 3 54 ± 6 <0.001 
Punjab, India 
31.2 
AD- D 
Controls- I 
Su 2017 [34] Case-Control 60 37 C 16 ± 7 40 ± 7 20 ± 10 49 ± 26 0.07 Turkey 
39 
AD- D 
Controls- D 
Wang 2014 
[26] Case-Control 498 328 C 11 ± 6 29 ± 15 14 ± 6 34 ± 15 <0.001 
Hong Kong 
22.4  
AD- D 
Controls- D 
Vitamin D status defined as a 25(OH)D—Deficiency <20 ng/mL (50 nmol/), Insufficiency 21–29 ng/mL (52.5–72.5 nmol/). Sufficiency >30 ng/mL (75 nmol/) [37]. 
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Table 3. Interventional studies of vitamin D supplementation in atopic dermatitis. 
Study Interventional Design Type Participants Population-n Primary Study Outcome 
p 
Value Secondary Outcome 
Serum 
25(OH)D 
Levels 
Baseline 
(nmol/L) 
VitD 
Deficient (D) 
Sufficient(S) 
Insufficient(I) 
Albenali 2016 
(U.K.) [38] 
Clinical service evaluation of AD and 
Eczema Herpeticum (ADEH). VitD 
supplementation based on deficiency 
and additionally 6000 IU/daily for age 
1–12 years, 10,000 IU/daily for age 12–
18 years. Baseline population: 57% 
with VitD def, 26% suboptimal levels 
and 83% insufficient VitD level 
Age 1–18 years 
n = 47, 
n-AD = 12, n-
ADEH = 35 
25(OH)D level and SCORAD showed significant inverse 
relationship (p = 0.01) r = −0.36. at baseline. After 2 months 
VitD supplementation, 42% reduction in SCORAD (p = 0.001) 
0.001 
Serum of AD was significantly 
correlated with LL-37 levels (r = 
−0.32 p = 0.01) suggesting causal 
relationship. LL 37 levels (known 
to help with re-epithelization) 
significantly different; reduced in 
severe AD, post-
supplementation. 
- - 
Amestejani 
2012 (Iran) [39] 
Randomized double-blind placebo 
controlled trial, 1600 IU/daily 
cholecalciferol given for 60 days 
Age 14 and older. 
Population n = 60  
n-VitD = 24 
n-placebo = 30 
Significant improvement of SCORAD and TIS (Three Item 
Severity Score) value under in VitD group of mild, moderate 
and severe AD (p < 0.005) not seen in placebo group (p > 0.05). 
 
<0.005   23 ± 3 D 
Di Filippo 2015 
(Italy) [29] 
Interventional study—prospective 
longitudinal 1000 IU/daily 3 months. 
Age 4 ± 3.15 year 
with AD and pre-
pubertal Tanner 
stage 1. 
n-AD = 39, final 
compliers AD = 
22,  
n-HC = 20 
Standard mean value of serum Vit D levels was insufficient 
and comparable with healthy controls. AD = 23 ± 8 HC = 20 ± 3. 
Improvement from baseline levels of serum 25(OH)D 
correlated with reduction in SCORAD index. Significant 
negative correlation between VitD change and SCORAD 
change (r = −0.49 p = 0.02)  
0.01 
In AD, high rate of VitD 
insufficiency (74%) and 
deficiency (7%). Improvement in 
VitD levels after 3 months 
correlated with reduction in 
SCORAD and reduced 
inflammatory cytokines. 
57 ± 20 I 
Hata 2014 
(U.S.A-
Multicenter) 
[35] 
Randomized double-blinded placebo 
controlled trial VitD3: 4000 IU/daily 
for 21 days 
AD interventional 
= 30 (mean age of 
31.2 year); placebo 
= 30 (mean age 
31.9 year) 
  
AD subject with Fitzpatrick Type V/VI skin had significantly 
lower serum 25(OH)D level 19 ng/mL comparing to type III/IV 
with a mean 25 OHD of 29 ng/mL (p = 0.04). Increase in serum 
25(OH)D from mean of 30 ng/mL to 40 ng/mL. p < 0.01 
0.05 
AD subject serum 25(OH)D 
inversely correlated with BMI (r = 
−0·31. p = 0.04). 
29 (11) D 
Javanbakht 
2011 (Iran) [40] 
Randomized double-blind placebo 
controlled trial. 1600 IU/daily for 60 
days  
Age 13–45, 
SCORAD 10–70,  
n-AD with VitD = 
12, n-placebo = 11 
SCORAD: significant reduction of 34.8% in VitD group, 
placebo group: 28.9%. Change in objective SCORAD: VitD 
group: 38·%, placebo group: 31%. Change in intensity 37% 
VitD group, 25% in placebo group. 
0.004 
No associate relationship with 
SCORAD and serum 
25(OH)VitD3 level. Strong 
reduction in usage of topical 
steroid. 
- - 
Samochocki 
2013 (Poland) 
[33] 
Interventional study from a cross-
sectional study not randomised or 
controlled. Blinding done for 
supplementation and SCORAD 
evaluation. 2000 IU/daily 3 months, 
Jan to March 
Age 18–50 years 
n-AD:95, n-HC:58 
observational, 
For 
interventional 
study n = 20 
Supplementation improved Vit D levels from deficient to 
insufficient levels, statistically significant decrease in AD 
severity (p < 0.05). All SCORAD parameters except 
lichenification significantly decreased. Correlation of 
improvement in SCORAD and VitD (p = 0.001) 
<0.05 
After 3 months supplementation 
mean total IgE level significantly 
lower than before (995 ± 1681 vs. 
1148 ± 19 IU/mL) p < 0.001. 
19 ± 8 D 
Tsotra 2017 
(Greece) [41] 
Interventional study 2 months, 
Vitamin D supplementation 1200 IU 
in mild AD (SCORAD < 40), 2400 IU 
in severe AD (SCORAD > 40) 
Children with AD, 
Severe and mild 
(no other 
information)  
n-AD: 50, 
Baseline SCORAD differed significantly between mild AD, 
severe AD group, p < 0.001. Post 20 days supplementation, the 
difference disappeared (p = 0.65) and statistically insignificant 
at 45 days (p = 0.61) and 60 days (p = 0.48). Significant 
“downregulation” of symptom severity in severe AD group on 
2400 IU/daily oral VitD supplementation. 
0.001 
Levels of serum cathelicidin child 
with AD significantly higher than 
those with children in control 
group. AD 61 (261–129) 
p = 0.02, HC 50 (0.2–93.6). No 
correlation seen with severity of 
SCORAD and baseline serum 
cathelicidin and cathelicidin in 
tissue preparation for atopic skin.  
- - 
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Udompataikul 
2015 (Thailand) 
[36] 
 Randomized double-blind placebo 
controlled trial VitD 2000 IU/daily. 
1–18 years old.  
Mean age 8–28 
years  
n-Vit D: 12, n-
placebo: 12 
Changes of VitD group vs. placebo group at week 4: 
Statistically significant reduction in SCORAD (p = 0.02), lower 
S. aureus colony count (p = 0.03). Statistically significant 
reduction in Erythema index (p = 0.01). Oedema, excoriation, 
pruritus better. lichenification, dryness and sleeplessness not 
better. Skin conductance not statistically significantly 
difference between group at each visit (p = 0.01, 0·65 and 0·55 
respectively) Serum VitD levels inversely correlate with 
SCORAD and S. aureus colonisation with statistically 
significant difference (r = −1.0, p = < 0.01). Obvious increment of 
25(OH)D levels in supplemented group compared to placebo 
group significant difference 8 mg/mL vs. 0·8 mg/mL (p = 0·01) 
0.02 
Significant reduction documented 
in S. aureus colonisation in 
Vitamin D group at week 4 vs. 
placebo group, p = 0.03 
43 D 
Vitamin D status defined as a 25(OH)D—Deficiency < 20 ng/mL (50 nmol/L), Insufficiency 21–29 ng/mL (52. 5–72. 5 nmol/L). Sufficiency >30 ng/mL (75 nmol/L) [37]. 
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Table 4. Data of interventional studies included in the meta-analysis. 
Study 
Age: 
Adult 
‘A‘ 
Child 
‘C’ 
n-
Cases 
n-
Controls 
Serum 
25(OH)D 
Levels 
Baseline(n/) 
Serum 
25(OH)D 
Levels after 
VitD 
Intervention 
(n/)  
SCORAD 
before 
Intervention 
SCORAD 
after 
Intervention 
Percentage 
Improvement of 
SCORAD 
p 
Value 
Trial 
Period 
in 
Months 
VitD 
Dosag
e IU. 
Percentag
e Weight 
of Study 
as per 
Forest Plot 
Calculatio
n of 
Weighted 
Mean Dose 
per Study 
(I.U) 
VitD 
Deficient (D) 
Sufficient(S) 
Insufficient(I) 
Amestejani 2012 [39]. A, C 24 24 23 ± 3 55.4 ± 10.8 25 ± 4 15 ± 3 38% <0.05 2 1600 31 496 D 
Di Filippo 2015 [29] C 22 22 57 ± 20 74 ± 26.8 46 ± 16 23 ± 15 51% 
<0.00
1 
3 1000 12.6 252 I 
Javanbakht 2011 [40] A,C 12 12 - - 36 ± 4 23 ± 3 35% 0.004 2 1600 11.5 115 - 
Samochocki 2013 [33] A 20 20 19 ± 8 33 ± 14 45 ± 16 26 ± 11 43% 0.001 3 2000 29.3 469 D 
Udompataikul 2015 
[36] 
C 12 12 43 63 18·± 9 8·± 9 56% 0.02 1 2000 15.6 312 D 
        
Weighted Mean Dose 
* 
   100% 1600  
Vitamin D status defined as a 25(OH)D—Deficiency <20 ng/mL (50 nmol/), Insufficiency 21–29 ng/mL (52. 5–72. 5 nmol/). Sufficiency >30 ng/mL (75 nmol/) [37].  
* rounded value. 
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Figure 1. PRISMA 2009 Flow Diagram to show results of the search process and inclusions/exclusions. 
3.2. Meta-Analysis 
3.2.1. Serum VitD in AD Compared to HC, with Sub-Analysis of the Paediatric Population 
Eleven studies were suitable for inclusion in the meta-analysis to compare serum 25(OH)D in 
AD compared to HC (Figure 2). Three studied a mixed population of adult and paediatric 
populations [31,32,35]. One study [33] studied an adult only population whilst seven studies 
documented serum 25(OH)D levels in paediatric populations only [25–30,34]. Figure 2 summarizes 
the meta-analysis for serum 25(OH)D in AD and HC, including eleven studies. The results showed a 
statistically significantly lower 25(OH)D concentration in AD patients than HC by −14 nmol/L (95% 
CI −25 to −2, p = 0.02; I2 = 99%). Very high heterogeneity was noted so a random effects model was 
used. 
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Figure 2. Forest Plot for meta-analysis of serum 25(OH)D levels in atopic dermatitis population 
compared with healthy controls (nmol/L). References: Cheon 2015 [27]. D’Auria 2017 [28]. Di Filippo 
2015 [29]. El Taeib 2013 [30]. Han 2015 [31]. Hata 2014 [35]. Noh 2014 [32]. Samochocki 2013 [33]. 
Sharma 2017 [25]. Su 2017 [34]. Wang 2014 [26]. 
A sensitivity analysis was performed (Table S3). The effect size stayed very stable when studies 
were removed in turn, except for being lower (around a 9 nmol/L group difference) when El Taieb et 
al. (2013) [30] was removed. Also, the removal of Cheon et al. (2015) [27], Wang et al. (2014) [26], and 
Sharma et al. (2017) [25] rendered the effect size not statistically significant. A further sensitivity 
analysis was done specifically for studies from common regions and ethnicities, including 3 studies 
from South Korea and two studies from Italy (Table S4). The effect size was not statistically significant 
when including only the Korean studies, although the magnitude of the effect was similar to when 
all studies were included (25(OH)D status was still around 14 nmol/L lower in the AD than in the 
non-AD group). The inclusion of only the Italian studies still gave a statistically significant result, 
with a similar effect size to that for all studies (16 nmol/L group difference). 
A sub-analysis by age was also conducted, separating the purely adult AD and paediatric AD 
populations with their same age HC (Figure 3). The sub-analysis for the paediatric population 
showed a statistically significantly lower serum 25(OH)D in AD children by 16 nmol/L compared to 
HC: −16 (95% CI −31 to −1, p = 0.05, I² = 99%). Considerable heterogeneity was noted (I2 = 99%) so a 
random effects model was used. The sub-analysis for the adult AD population did not show a 
statistically significant result: −2 nmol/L (95% CI −5 to 1, p = 0.15, I² = 0%). The effect size for the adult 
population studies may need to be interpreted with caution due to presence of few included studies 
and a small population (n = 168 AD vs. n = 151 HC) due to limited data available. 
 
Figure 3. Forest Plot of comparison of serum 25(OH)D levels (nmol/L) in adult and paediatric atopic 
dermatitis populations versus their age-matched healthy controls, with sub-analysis by age group. 
References: Cheon 2015 [27]. D’Auria 2017 [28]. Di Filippo 2015 [29]. El Taeib 2013 [30]. Han 2015 
[31]. Hata 2014 [35]. Noh 2014 [32]. Samochocki 2013 [33]. Sharma 2017 [25]. Su 2017 [34]. Wang 
2014 [26]. 
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Finally, the overall adult and child sub-analysis showed a statistically significantly lower 
25(OH)D mean difference in AD patients by −13 nmol/L (95% CI −25 to −0.04, p = 0.08; test for 
subgroup difference I2 = 68%, p = 0.08) (Figure 3). Of note, this result differs slightly from Figure 2 
due to the differential weighting of each study when split by age group and then the adult and child 
estimates are pooled compared with when there is no split by age group. 
Funnel plots for the analyses represented in Figures 1 and 2 were conducted (Supplementary 
Figures S1 and S2). Both plots showed asymmetry with relatively few studies with positive effect 
sizes (i.e., case serum 25(OH)D higher than control) suggesting possible publication bias. 
3.2.2. VitD Interventional Trials and Change in Clinical AD Severity (SCORAD) 
A meta-analysis was conducted for five interventional trials in AD cases with the primary 
outcome of change in SCORAD index after intervention compared to baseline (Figure 4). Two trials 
were from a combined adult and paediatric population [39,40]. One trial was from a purely adult 
population [33] while two trials were from paediatric AD populations [29,36]. The analysis was 
performed as two subgroups as the results from repeated measures interventions (i.e., patients are 
their own control) could not be statistically combined with studies that involved two groups of 
individuals (intervention vs. placebo). 
For the repeated measures interventions, there was a highly statistically significant reduction in 
SCORAD by 21 points on intervention with VitD, (mean difference = −21 points (95% CI −27 to −15, p 
< 0·0001; I2 = 0%) with a weighted mean dose of 1500 IU/daily. For the randomised control trials, there 
was a highly statistically significant reduction in SCORAD by 11 points on intervention with VitD, 
(mean difference = −11 points (95% CI −13 to −9, p < 0.0001; I = 32%) with a weighted mean dose of 
1600 IU/daily (Figure 4). The random effects model was used for the analyses as substantial 
heterogeneity was seen between studies for the randomised control trials. A sensitivity analysis was 
performed (Table S5), removal of each study in turn only had a small effect on effect size and no effect 
on statistical significance. 
Though the number of studies were few, all studies showed improvement in SCORAD index on 
supplementation with VitD. It should be noted that in these five studies the AD population consisted 
mostly of mild and moderate AD with few severe cases in two of the studies. 
A sub-analysis by dosage and duration for the five trials (Supplementary Figure S3) showed a 
greater change in Di Filippo et al. (2015) [29] and Samochocki et al. (2013) [33], which were both of 
three month duration and repeated measures, compared with the other trials which were randomised 
control trials and only one to two months duration. In the paediatric Di Filippo et al. (2015) [29] study, 
VitD dosage was 1000 IU/daily compared with 2000 IU/daily in the adult Samochocki et al. (2013) 
[33] trial. This sub-analysis must be interpreted with caution due to the limited number of studies, 
with substantial heterogeneity. Overall, it is noted that the three-month trials contained mostly mild–
moderate AD patients, were repeated measures studies rather than randomised control trials and 
showed higher mean reduction in SCORAD than the one to two month studies. 
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Figure 4. Meta-analysis of vitamin D intervention trials in atopic dermatitis: Comparison of clinical 
SCORAD index at baseline and post-vitamin D supplementation. References: Amestejani 2012 [39]. 
Di Filippo 2015 [29]. Javanbakht 2011 [40]. Samochocki 2013 [33]. Udompatailkul 2015 [36]. 
4. Discussion 
Our findings show a lower serum 25(OH)D concentration by 14 nmol/L in the overall adult and 
paediatric AD population than in HC, with lower serum 25(OH)D also in the AD paediatric 
population by 16 nmol/L. There was no difference in the adult population alone, the effect size for 
which did not reach statistical significance. Therefore, our study shows that the AD population have 
lower 25(OH)D concentration than their healthy peers, particularly for children. Our results suggest 
that the AD paediatric population may be an “at-risk group” for VitD insufficiency. As per US 
Endocrine Society guidelines, all individuals at risk of vitD insufficiency must be assessed routinely 
for 25(OH)D status [37]. This should be considered as best practice during the diagnosis and 
treatment of the AD paediatric population. VitD supplementation may be considered by the clinician 
taking into account baseline 25(OH)D status and possible contraindications (e.g., endocrine 
dysfunction). 
Pooling results from repeated measures clinical trials in AD patients, post-supplementation we 
found a highly statistically significant difference between supplement and placebo groups in 
SCORAD of −21 points, using dosages of 1000–2000 IU daily for three months. Similarly, pooling 
results from VitD randomised control trials in AD patients, post-supplementation we found a highly 
statistically significant difference between supplement and placebo groups in SCORAD of −11 points, 
using dosages of 1000–2000 IU daily for one to two months. 
In intervention trials, the minimal difference or improvement set as a measure of effectivity of 
the intervention is called the Minimal Clinical Important Difference or MCID. For the treatment of 
atopic dermatitis, the MCID of the SCORAD score which translates to clinical relevance is a reduction 
of 9 points [42]. Our effect size of −11 to 21 points exceeds this threshold, suggesting clinical relevance. 
Therefore, we have found clear evidence for a clinically meaningful reduction in AD disease severity 
after VitD supplementation. Of note, the baseline average (mean or median) 25(OH)D for all 
intervention trials in the meta-analysis was <50 nmol/L, which would be classified as deficient [33,37]. 
This shows that the trials included individuals who were truly deficient in 25(OH)D at baseline, so 
were not (on average) supplementing individuals who already had sufficient 25(OH)D status. After 
supplementation, this average 25(OH)D was >50 nmol/L in all trials except one [33]. 
Bearing in mind the clinical background of the each patient, including individual 25(OH)D 
concentration and any existing endocrine issues, this research supports the empirical 
supplementation of daily VitD doses of approximately 1500–1600 IU/daily to AD patients, taking into 
account the baseline vitamin D levels and eventual endocrine issues or other concomitant diseases 
that contraindicate vitamin D supplementation. 
This weighted mean of 1500–1600 IU (38–40 micrograms) daily dosage falls well below the 
European Food Standards Agency (EFSA) Tolerable Upper Intake Levels (UL) of 100 micrograms per 
day for all adults as well as children aged 11–17 years [43]. It also falls below the UL for 1–10 year old 
children (50 micrograms per day) [43] but is higher than the UL for infants (25 micrograms per day) 
[43]. Clinical biochemical monitoring should be undertaken of children receiving 1500–1600 IU (38–
40 micrograms per day) due to it being closer to their UL (50 micrograms per day) and infants should 
definitely not be given 1500–1600 IU/daily. Indeed, the UL is not a target, and is based on population 
(not individual) safety. Clinicians should make their own judgements about safe intakes for their 
individual patients, bearing in mind the effective dose suggested by this study (1500–1600 IU/daily). 
In our analysis, larger results were seen in trials of three month duration but from the limited 
data available we were not able to assess whether this was due to the 3 month duration itself, or if it 
was simply that all the three month studies were repeated measures studies, rather than full 
randomised placebo control trials. Nevertheless, it stands to logical reason that supplementing for 
three months, rather than one to two months, is likely to lead to a better clinical response. 
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In terms of previous systematic reviews and meta-analyses in the field, our work supports the 
findings of systematic reviews by Kim et al. (2016) [12], Kim and Bae (2016) [23], Huang et al. (2018) 
[24] and Vaughn et al. (2019) [44] in terms of finding a lower 25(OH)D status in AD patients than 
controls, and finding an effect of vitamin D supplementation on symptom severity. 
Our textual systematic review indicated that most interventional trials have documented a 
reduction in skin infection after VitD supplementation. Some observational evidence also suggested 
an association between lower 25(OH)D concentration and increased cutaneous secondary-
colonisation of S. aureus and herpes, suggesting that increasing 25(OH)D levels in the AD population 
may support the reduction of and prevention of secondary cutaneous infections, albeit this was based 
on a small number of studies and there was not enough data to perform a meta-analysis. 
In terms of biological mechanisms, it is feasible that VitD could affect the severity of AD, 
including number of infections. VitD is known to modulate innate and adaptive immune responses 
[45]. The physiological role of VitD in supporting healthy skin [20], as well as the fact that lower 
25(OH)D concentrations are known to correlate with increased allergic sensitisation [46], higher IgE 
level [47], and lower serum cathelicidin levels [48], suggest a role of VitD in modulating AD severity. 
Moreover, studies involving the disruption of the VDR have showed lower levels of involucrin, 
profilaggrin and loricin barrier proteins [49]. Improvement in 25(OH)D leads to upregulation of 
functional human cathelicidin (hCAP18) in keratinocytes from AD patients, as well as from those 
from patients with psoriasis and normal skin [50]. In support of the above mechanisms, Albenali et 
al. (2016) [38] showed that higher Ig E levels, higher virulence and colonisation of S. aureus were 
recorded when serum 25(OH)D levels were low. A significantly increased risk of having skin lesions 
with methicillin-resistant S. aureus (MRSA) has been found in persons with VitD deficiency [51–53]. 
Udompataikul et al. (2015) [36] found a reduction in S. aureus colonization in a paediatric population 
on VitD supplementation while Samochocki et al. (2013) [33] found no incidence of infection in their 
adult supplemented population. Albenali et al. (2016) [38] observed a 4-fold upregulation of LL-37 in 
the stratum corneum on VitD supplementation and a reduction in AD complicated by eczema 
herpeticum. 
Secondary infections and re-infections in AD are notoriously challenging to treat, with excess 
use of topical and oral antibiotics increasing the risk of microbial antibiotic resistance. A recently 
published study [54] analysed eleven-year nationally representative data and calculated the 
morbidity, mortality and cost of secondary infections in AD to be in excess of 11 to 228 million USD 
annually. Improving 25(OH)D levels in AD may support the war on antibiotic resistance by reducing 
the risk and severity of cutaneous infections. However, a lot more research is needed on this subject 
due to the small amount of currently published literature. 
In terms of strengths, our systematic review and meta-analysis is the most up to date available 
on the role of VitD in AD in both adults and children. It calculated pooled effect sizes in terms of 
mean difference in serum 25(OH)D levels between the AD population and HC. Our effect size is also 
larger than the mean difference found in the other meta-analysis by Kim and Bae (2016) [23]. Our 
review is the first to document clinically relevant changes in disease severity (as assessed by 
SCORAD) after VitD supplementation. 
In terms of limitations, it is important to note that the data from trials in our analysis included 
mainly mild and moderate AD with only a few severe cases. Also, no data from infants (<1 year of 
age) or pregnant women were included. The specific reduction in SCORAD seen, and difference in 
25(OH)D between AD patients and HC may differ in these groups from that found in this review. 
Finally, our results are based on a mean weighted dose of around 1500–1600 IU per day and SCORAD 
reductions observed seen are likely to differ with higher or lower doses. 
Three trials [35,38,41] could not be included in the meta-analysis due to no reporting of the 
standard deviation for SCORAD. These happened to be the higher dose trials and so this limited our 
analysis to trials with dosage ranges of 1000 IU–2000 IU/daily. Six trials confirmed the form of VitD 
given as VitD3 or VitD2, but two trials did not report the form of VitD used. The longest trials were 
only of three months duration hence the effect of longer-term supplementation could not be analysed. 
Our meta-analysis of 25(OH)D concentration in AD compared to HC was limited by the small sample 
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size, especially for the adult population. Similarly, the meta-analysis of the interventional studies was 
limited by the small number of trials suitable for inclusion. 
Quality analysis of the interventional studies showed four higher scoring randomised double 
blind clinical trials with mention of adequate randomisation and blinding [35,36,39,40]. In terms of 
the other studies, one study was designed as a clinical evaluation study and so was not a randomised 
clinical trial, [38] and Samochocki et al. (2013) [33] did not mention randomisation but confirmed 
blinding of both participants and researchers. Di Filippo et al. (2015) [29], Albenali et al. (2016) [38] 
and Tsotra et al. (2017) [41] did not mention randomisation or blinding of participants. 
There was some potential evidence of publication bias in that there was asymmetry in the funnel 
plots, with very few studies having positive effect sizes (i.e., cases having higher serum 25(OH)D 
than controls). However, the funnel plots only contained a small number of studies (n = 11 or n = 12) 
so they must be interpreted with caution. The number of interventional studies were too few to judge 
publication bias so there may still be a possibility of unpublished studies with null findings, despite 
best efforts being made to locate unpublished data. In some trials, the limited information on form of 
VitD supplemented (D2 vs. D3) and the absence of information on ingredient type and source of the 
D2 or D3 prevented further analysis in this regard. 
In terms of further research, there is an urgent need for longer term, well conducted trials in 
distinct age categories, at different severity levels and also for different histopathological disease 
stages. Intervention trials with VitD dosage titration based on the severity of the disease, concomitant 
cytokines, the cell landscape and dermal cathelicidin levels are also needed. Trials designed to 
understand the link between VitD supplementation, skin barrier function and innate immunity to 
reduce secondary cutaneous infections in AD would help provide evidence that may justify the need 
for VitD supplementation to modulate the prevalence of microbe colonisation and reduce the need 
for antibiotics in these patients. Studies assessing effects of VitD supplementation on topical steroid 
usage would also be useful as reduced usage of steroids would have cost benefits. If optimal serum 
25(OH)D levels could indirectly support the reduction of antibiotic usage and curtail antibiotic 
resistance, further research in this area is clearly urgently required. Particularly, research 
investigating and quantifying the effect of VitD on gut and skin microbiota may support 
supplementation as a possible preventative and adjuvant treatment strategy. 
Further trials with specifically vitamin D3 vs. D2 may provide data to support form dosage and 
time period of the supplementation for fastest recovery with least risk. Assessing the source and 
ingredients in vitamin D supplements used in trials may shed new light on a population known for 
sensitisation especially in the younger years. VitD3 forms of supplements are likely to support a more 
efficient increase in serum 25(OH) levels [55] but are usually derived from lanolin (from sheep’s 
wool). 
Finally, the textual systematic review suggested that studies of VitD supplementation in mild to 
moderate AD did not show changes in pruritus (based on SCORAD), skin xerosis, lichenification, 
skin conductance and moisture levels of skin [36]. This suggests the need for investigating other 
possible treatment strategies including, possibly targeting specific cytokines, such as monoclonal 
antibodies against IL-31 to reduce pruritus, as well as the use of nutritional factors, to support AD 
therapy. 
5. Conclusions 
Our study shows significantly lower 25(OH)D levels in the AD population, especially the 
paediatric subset. Monitoring of 25(OH)D levels in AD patients is warranted, especially in children. 
VitD supplementation trials showed clinically relevant improvements at a weighted average dose of 
1500–1600 IU for up to 3 months. Clinicians should consider appropriate supplementation after 
evaluating patients’ 25(OH)D concentration and medical history. Further research is required to 
establish the efficacy of vitamin D2 vs. D3 in reducing AD severity, as well as the effects of VitD 
supplementation on infection rates, including superinfections and topical steroid usage. 
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